Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Non-Current Liabilities (2017 - 2025)

Arcus Biosciences has reported Other Non-Current Liabilities over the past 9 years, most recently at $135.0 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $135.0 million for Q4 2025, down 14.01% from a year ago — trailing twelve months through Dec 2025 was $135.0 million (down 14.01% YoY), and the annual figure for FY2025 was $135.0 million, down 14.01%.
  • Other Non-Current Liabilities for Q4 2025 was $135.0 million at Arcus Biosciences, down from $152.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for RCUS hit a ceiling of $166.0 million in Q1 2025 and a floor of $10.2 million in Q1 2021.
  • Median Other Non-Current Liabilities over the past 5 years was $139.0 million (2022), compared with a mean of $104.8 million.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 22367.77% in 2021 and later decreased 14.01% in 2025.
  • Arcus Biosciences' Other Non-Current Liabilities stood at $122.0 million in 2021, then increased by 14.75% to $140.0 million in 2022, then increased by 1.43% to $142.0 million in 2023, then grew by 10.56% to $157.0 million in 2024, then dropped by 14.01% to $135.0 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $135.0 million (Q4 2025), $152.0 million (Q3 2025), and $159.0 million (Q2 2025) per Business Quant data.